Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.

Authors:
Kazufumi Kobayashi Sadahisa Ogasawara Aya Takahashi Yuya Seko Hidemi Unozawa Rui Sato Shunji Watanabe Michihisa Moriguchi Naoki Morimoto Satoshi Tsuchiya Kenji Iwai Masanori Inoue Keita Ogawa Takamasa Ishino Terunao Iwanaga Takafumi Sakuma Naoto Fujita Hiroaki Kanzaki Keisuke Koroki Masato Nakamura Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba

Liver Cancer 2022 Jan 6;11(1):48-60. Epub 2021 Dec 6.

Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Background And Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been fully verified yet.

Approach And Results: We retrospectively collected the data on the whole clinical course of 877 patients who received any MTAs as first-line systemic therapy for advanced HCC between June 2009 and March 2019. The study population was divided into 3 groups according to the date of first-line MTA administration (period 1: 2009-2012, = 267; period 2: 2013-2016, = 352; period 3: 2017-2019, = 258). Then, we compared the number of MTAs used, overall survival (OS), and MTA treatment duration among the 3 groups. Analysis was also performed separately for advanced-stage and nonadvanced-stage HCC. The proportion of patients who received multiple MTAs was remarkably increased over time (1.1%, 10.2%, and 42.6% in periods 1, 2, and 3, respectively, < 0.001). The median OS times were prolonged to 10.4, 11.3, and 15.2 months in periods 1, 2, and 3, respectively ( = 0.016). Similarly, the MTA treatment durations were extended (2.7, 3.2, and 6.6 months in periods 1, 2, and 3, respectively; < 0.001). We confirmed that the correlation between OS and MTA treatment duration was strengthened (period 1: 0.395, period 2: 0.505, and period 3: 0.667). All these trends were pronounced in the patients with advanced-stage HCC but limited in the patients with nonadvanced-stage HCC.

Conclusions: The availability of multiple MTAs had steadily improved the prognosis of patients with advanced HCC patients, particularly advanced-stage HCC patients.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000519868DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820147PMC
January 2022

Publication Analysis

Top Keywords

mta treatment
12
patients advanced
12
patients
9
hcc patients
8
periods 0001
8
patients received
8
advanced-stage hcc
8
prognosis patients
8
patients advanced-stage
8
hepatocellular carcinoma
8
advanced hcc
8
advanced hepatocellular
8
multiple mtas
8
treatment duration
8
molecular target
8
months periods
8
target agents
8
mtas
6
hcc
6
period
6

Keyword Occurance

Similar Publications

A magzatok intrapartum monitorizálásának lehetőségei elhízott várandósokban.

Authors:
Sándor Rácz Kálmán Kovács József Bódis Bálint Farkas

Orv Hetil 2022 Aug 14;163(33):1311-1317. Epub 2022 Aug 14.

1 Pécsi Tudományegyetem, Szülészeti és Nőgyógyászati Klinika Pécs, Édesanyák útja 17., 7624 Magyarország.

Obesity, as an epidemic, is one of the major public health challenges of the 21st century. It affects more and more people annually, and through its numerous negative psychological and physical effects as a risk factor it increases the morbidity and mortality of several diseases. It has a major impact on pregnancy; it is well established that both infertility and abortion is more common among obese women. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-element binding proteins.

Authors:
Baiqing Tang Hyung-Ok Lee Sapna Gupta Liqun Wang Alison M Kurimchak James S Duncan Warren D Kruger

J Biol Chem 2022 Aug 10:102367. Epub 2022 Aug 10.

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111. Electronic address:

Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway that converts the polyamine synthesis byproduct 5'-deoxy-5'-methylthioadenosine (MTA) into methionine. Inactivation of MTAP, often by homozygous deletion, is found in both solid and hematologic malignancies and is one of the most frequently observed genetic alterations in human cancer. Previous work established that MTAP-deleted cells accumulate MTA and contain decreased amounts of proteins with arginine residues symmetrically dimethylated (sDMA). Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Multiple growth factors accommodated degradable submicron calcium sulfate hemihydrate/porous hydroxyapatite for dentin-pulp regeneration.

Authors:
Chih-Wen Chi Bharathi Priya Lohanathan Ching-Ching Wong Che-Lun Chen Hsun-Chang Lin Yu-Chih Chiang

Biomater Adv 2022 Jul 26;140:213045. Epub 2022 Jul 26.

School of Dentistry and Graduate Institute of Clinical Dentistry, National Taiwan University and National Taiwan University Hospital, Taipei 10016, Taiwan; School of Dentistry, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. Electronic address:

Vital pulp therapy (VPT) has gained significant consideration by utilizing the natural healing capacity of the inflamed pulp in healing process. However, the protective pulp capping materials that facilitate this healing process are still under investigation for the successful promotion of dentin-pulp regeneration. Herein, we developed a bioactive and biodegradable pulp capping material (denoted as sCSHA-GFs) by synthesizing inorganic submicron calcium sulfate hemihydrate (sCS)/porous hydroxyapatite (HA) loaded with growth factors (GFs) such as transforming growth factor-beta 1 (TGF-β1), fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Read More

View Article and Full-Text PDF
July 2022
Similar Publications

Effect of three intracanal medicaments used in pulp regeneration on the push-out bond strength of mineral trioxide aggregate and calcium-enriched mixture: An study.

Authors:
Negin Ghasemi Hamidreza Yavari Mohammad Samiei Naser Asl Aminabadi Fatemeh Dabbaghi Tabriz Samra Taheri Paria Davoudi

J Dent Res Dent Clin Dent Prospects 2022 29;16(1):40-44. Epub 2022 May 29.

Department of Endodontics, Faculty of Dentistry, Shahid Beheshti Medical University, Tehran, Iran.

The bond strength of the materials used as a cervical barrier in the pulp regeneration is essential for the success of treatment. This study aimed to evaluate the effects of triple antibiotic paste (TAP), double antibiotic paste (DAP), and simvastatin as intracanal medicaments on the dislodgement resistance of mineral trioxide aggregate (MTA) and calcium-enriched mixture (CEM). A total of 160 extracted human single-rooted teeth were selected, and root canal preparation was carried out. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).

Authors:
Takuya Higashiyama Kiminori Sugino Hisato Hara Ken-Ichi Ito Noriaki Nakashima Naoyoshi Onoda Masayuki Tori Hiroshi Katoh Naomi Kiyota Ichiro Ota Nobuyasu Suganuma Yatsuka Hibi Toshimitsu Nemoto Shunji Takahashi Katsunari Yane Tetsuya Ioji Shinsuke Kojima Hideaki Kaneda Iwao Sugitani Makoto Tahara

Eur J Cancer 2022 Aug 3;173:210-218. Epub 2022 Aug 3.

Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Purpose: Anaplastic thyroid cancer (ATC) is a rare and highly aggressive cancer for which effective systemic therapy has long been sought. Here, we assessed the efficacy and safety of lenvatinib in patients with unresectable ATC.

Patients And Methods: The study was investigator-initiated and conducted under a multicenter, open-label, nonrandomized, phase II design. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap